Evicenter
P&T meetings

Atebrioz (zilurgisertib)

Fibrodysplasia ossificans progressiva

Also known as INCB000928
Regulatory submission
NDA submitted by May 2026
Last updated
96 sources

Product information and disease descriptionProduct descriptionProduct information

Co-prescribed/Concomitant therapies

2 evidence topics · 1 source

Iron supplements

“No significant differences in mean ferritin change from baseline was observed between ATEBRIOZ- and placebo-treated patients, including patients who took iron supplements.” (opens the prescribing information at this quote)

Review of concomitant medications and supplements

“Advise patients to inform their healthcare providers of all concomitant medications, herbal and dietary supplements” (opens the prescribing information at this quote)

Concomitant use with other FOP therapies

No evidence found.